Amphastar Pharmaceuticals (AMPH)
(Delayed Data from NSDQ)
$50.53 USD
-0.25 (-0.49%)
Updated Oct 31, 2024 04:00 PM ET
After-Market: $50.57 +0.04 (0.08%) 7:34 PM ET
3-Hold of 5 3
A Value B Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$50.53 USD
-0.25 (-0.49%)
Updated Oct 31, 2024 04:00 PM ET
After-Market: $50.57 +0.04 (0.08%) 7:34 PM ET
3-Hold of 5 3
A Value B Growth F Momentum B VGM
Zacks News
Wall Street Analysts Think Amphastar (AMPH) Is a Good Investment: Is It?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Amphastar (AMPH). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
The Zacks Analyst Blog Highlights Amphastar Pharmaceuticals, Journey Medical, Centessa Pharmaceuticals and Aquestive Therapeutics
by Zacks Equity Research
Amphastar Pharmaceuticals, Journey Medical, Centessa Pharmaceuticals and Aquestive Therapeutics are part of the Zacks top Analyst Blog.
Zacks.com featured highlights include Amphastar Pharmaceuticals, Shift4 Payments, Beacon Roofing Supply, Hooker Furnishings and Hilltop Holdings
by Zacks Equity Research
Amphastar Pharmaceuticals, Shift4 Payments, Beacon Roofing Supply, Hooker Furnishings and Hilltop Holdings are part of the Zacks Screen of the Week article.
Tenet Healthcare (THC) Gains 60% in a Year: More Room to Run?
by Zacks Equity Research
Diversified treatment network, solid patient volumes in the Hospital segment and robust cash flows continue to drive Tenet Healthcare (THC).
What Awaits These 4 Drug Stocks That More Than Doubled in 2023?
by Ahan Chakraborty
Here are four drug, biotech stocks, AMPH, DERM, CNTA & AQST, which have more than doubled in 2023 with room for further growth in 2024.
5 Good Opportunities on Relative Price Strength Strategy
by Nilanjan Choudhury
AMPH, FOUR, BECN, HOFT and HTH are five stocks with explosive relative price strength.
3 Reasons Why Amphastar (AMPH) Is a Great Growth Stock
by Zacks Equity Research
Amphastar (AMPH) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Centene (CNC) Ties Up to Aid Its Marketplace Members in Chicago
by Zacks Equity Research
Centene's (CNC) product - Ambetter of Illinois - along with RUSH aim to provide improved access to quality healthcare services for CNC's members in Chicago, and thereby grow its Marketplace business.
What's in Store for Nasdaq in 2024? 5 Top Picks
by Sanghamitra Saha
After a strong 2023, we expect the Nasdaq to log gains in 2024. Top-ranked Nasdaq stocks GigaCloud Technology Inc (GCT), Carrols Restaurant Group (TAST), Limbach (LMB), Amphastar Pharmaceuticals (AMPH) and Insight Enterprises Inc (NSIT) could emerge as winning picks.
Snap These 4 Top-Performing Liquid Stocks for Strong Returns
by Vaishali Doshi
Here are four top-ranked liquid stocks, Puma Biotechnology (PBYI), Amphastar Pharmaceuticals (AMPH), DropBox (DBX) and GigaCloud Technology Inc. (GCT), which investors can add to their portfolio for solid gains.
3 Reasons Why Growth Investors Shouldn't Overlook Amphastar (AMPH)
by Zacks Equity Research
Amphastar (AMPH) could produce exceptional returns because of its solid growth attributes.
Is Atossa Genetics (ATOS) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Atossa Genetics Inc. (ATOS) and Amphastar Pharmaceuticals (AMPH) have performed compared to their sector so far this year.
Zacks.com featured highlights Abercrombie & Fitch, Amphastar and NetEase
by Zacks Equity Research
Abercrombie & Fitch, Amphastar and NetEase have been highlighted in this Screen of The Week article.
Are You Looking for a Top Momentum Pick? Why Amphastar Pharmaceuticals (AMPH) is a Great Choice
by Zacks Equity Research
Does Amphastar Pharmaceuticals (AMPH) have what it takes to be a top stock pick for momentum investors? Let's find out.
Why You Should Retain UnitedHealth Group (UNH) Stock Now
by Zacks Equity Research
Growing membership, expanding government business, strategic acquisitions, improving operating margin and solid growth outlook poise UnitedHealth Group (UNH) well for growth.
3 Best Momentum Stocks to Buy Using the Driehaus Strategy
by Tirthankar Chakraborty
Stocks like Abercrombie & Fitch (ANF), Amphastar Pharmaceuticals (AMPH) and NetEase (NTES) have been selected as the momentum picks for the day using the Driehaus strategy.
Centene (CNC) Wins Contract From Arizona's Medicaid Agency
by Zacks Equity Research
Centene's (CNC) Arizona subsidiary has been chosen by the AHCCCS to improve health outcomes for the state's ALTCS-E/PD members and further solidify statewide presence.
4 Top-Performing Liquid Stock Picks for Robust Returns
by Vaishali Doshi
Here are four top-ranked liquid stocks, Puma Biotechnology (PBYI), Amphastar Pharmaceuticals (AMPH), DropBox (DBX), and Vimeo (VMEO), which investors can add to their portfolio for solid gains.
Amphastar (AMPH) Is Considered a Good Investment by Brokers: Is That True?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Amphastar (AMPH). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Here's Why Investors Should Retain Molina Healthcare (MOH) Now
by Zacks Equity Research
Molina Healthcare (MOH) is well-poised for improvement on the back of membership growth in the Medicaid and Medicare businesses. Acquisitions and a solid cash balance act as added tailwinds.
Here's Why You Should Invest in Centene (CNC) Stock Now
by Zacks Equity Research
Robust growth outlook, contract wins, accretive acquisitions and streamlining of businesses poise Centene (CNC) well for growth.
3 Reasons Why Growth Investors Shouldn't Overlook Amphastar (AMPH)
by Zacks Equity Research
Amphastar (AMPH) possesses solid growth attributes, which could help it handily outperform the market.
Are Medical Stocks Lagging Cencora, Inc. (COR) This Year?
by Zacks Equity Research
Here is how Cencora (COR) and Amphastar Pharmaceuticals (AMPH) have performed compared to their sector so far this year.
Wall Street Analysts See Amphastar (AMPH) as a Buy: Should You Invest?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Amphastar (AMPH). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Amphastar Pharmaceuticals (AMPH) Rises Yet Lags Behind Market: Some Facts Worth Knowing
by Zacks Equity Research
In the most recent trading session, Amphastar Pharmaceuticals (AMPH) closed at $45.27, indicating a +0.2% shift from the previous trading day.